LBBAP Versus ILR in Patients With New-Onset LBBB and Moderately Reduced LVEF After TAVI (LBB(AP)TAVI)
Comparison of Left Bundle Branch Area Pacing (LBB(AP)) and Implantable Loop Recorder (ILR) in Patients With New-onset Left Bundle Branch Block and Moderately Reduced LVEF After Transcatheter Aortic Valve Implantation (TAVI): A Randomized Multicenter Study.
Patients with new-onset complete LBBB (QRS > 120 ms, persisting > 24 h after TAVI) and moderately reduced LVEF (35-50%) will be screened in participating centers.
Eligible patients will be centrally randomized 1:1 (stratified by center and atrial fibrillation (yes/no)) to either:
- Experimental arm: Left bundle branch area pacing (LBB(AP)) with Biotronik pacemaker and dedicated conduction system pacing leads.
- Control arm: Implantable loop recorder (ILR, Biotronik BIOMONITOR IV) for rhythm monitoring.
The occurrence of the following events within 12 months of randomization will be evaluated: hospitalization for heart failure, syncope or hemodynamically significant dizziness, or high-grade atrioventricular conduction disturbance.
The impact of LBB(AP) compared to ILR monitoring will be evaluated at 6, 12, 24, and 36 months regarding: incidence of atrial fibrillation; incidence of non-sustained ventricular tachycardia; evolution of left ventricular ejection fraction; quality of life; hospitalizations; mortality; medico-economic outcomes; qccurrence of high-grade AV conduction disorders beyond 12 months; omplications related to pacemaker or ILR implantation; unscheduled pacemaker implantation in the ILR group.
Patients will be monitored following a regular schedule that includes clinical visits, transthoracic echocardiography , ECG, remote device monitoring, and EQ-5D at 6, 12, 24 and 36 months.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Lise Laclautre
- 电话号码:+33473754963
- 邮箱:promo_interne_drci@chu-clermontferrand.fr
学习地点
-
-
-
Angers、法国、49000
- CHU d'Angers
-
首席研究员:
- Antoine POIRIER
-
Clermont-Ferrand、法国、63000
- Chu Clermont Ferrand
-
首席研究员:
- Romain ESCHALIER
-
接触:
- Lise Laclautre
- 邮箱:promo_interne_drci@chu-clermontferrand.fr
-
Dijon、法国、21000
- CHU de DIJON
-
首席研究员:
- Fabien GARNIER
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients with new-onset complete left bundle branch block (LBBB) defined as QRS duration >120 ms, occurring after TAVI and persisting for >24 hours on ECG. New-onset complete LBBB will be confirmed by QRS duration >120 ms together with standard morphological criteria (broad, notched or slurred R waves in leads I, aVL, V5 and V6, with absence of Q waves in V5-V6), assessed by the site cardiologist and confirmed by the adjudication committee, in line with current ESC and ACC/AHA/HRS recommendations.
- Left ventricular ejection fraction (LVEF) between 35% and 50%, assessed within one month before TAVI, in a stable hemodynamic state.
- Patients implanted with a self-expanding or balloon-expandable valve.
- Age ≥ 18 years.
- TAVI procedure performed according to current ESC guidelines. The applicable reference is the 2025 ESC/EACTS Guidelines for the management of valvular heart disease (Praz, et al. Eur Heart J. (2025) 46, 4635-4736), or any subsequent official ESC update in force at the time of each patient's procedure.
- Life expectancy > 1 year.
- Affiliation to a social security scheme
- Written informed consent provided before study enrollment.
Exclusion Criteria:
- Permanent pacemaker implantation (PPI) before TAVI.
- Complete atrioventricular block after TAVI leading to immediate PPI.
- Permanent pacemaker implantation after TAVI for another indication (non-protocol).
- Pre-existing LBBB before TAVI.
- Trans-venous permanent pacemaker implantation: No superior vena cava access or mechanical tricuspid valve.
- Pregnancy or breastfeeding.
- No affiliation to a social security scheme.
- Refusal to participate or withdrawal of informed consent.
- Incapacity to consent.
- Adults under legal protection (trusteeship, guardianship, curatorship).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Left bundle branch area pacing with pacemaker and conduction system pacing (AMVIA SKY DR-T device)
|
LBB(AP) procedure will be performed by experienced operators according international guidelines and expert consensus. The implantation technique will be those used routinely in these expert centers. The procedure will begin with a vein access (axillary, sub-clavian or cephalic). The atrial, if necessary, will be implanted as usual practice. LBB(AP) lead will be implanted as recommended. LBB(AP) positioning criteria, as described in reference clinical studies, will be checked in order to differentiate between LBB(AP) and deep septal pacing. |
|
其他:Implantable loop recorder for rhythm monitoring (ILR, Biotronik BIOMONITOR IV Device)
Control arm |
ILR Procedure will be performed by experienced operators according international guidelines and expert consensus. The implantation technique will be those used routinely in these expert centers. The implanted device will be a Biomonitor IV (Biotronik, Berlin, Germany) and next generation if necessary. The implantable Loop Recorder is a single-lead ECG monitor of small size with long-term functionality (approximately 3 to 5 years). It is implanted under local anesthesia in the subcutaneous space of the left thoracic region (incision at the level of the 4th left intercostal space at a 45° angle). |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The first occurrence of one of the following events : hospitalization for worsening heart failure, episode of syncope or dizziness, high-grade atrioventricular conduction disturbance)
大体时间:From randomization to 12 follow up
|
The primary efficacy endpoint is a composite clinical outcome evaluated at 12 months after randomization, defined as the first occurrence of one of the following events:
The composite endpoint will be analyzed as time-to-event data with death considered as a competing risk. |
From randomization to 12 follow up
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of atrial fibrillation, ventricular tachycardia, non-sustained ventricular tachycardia
大体时间:At 6,12, 24 and 36 months after randomization
|
At 6,12, 24 and 36 months after randomization
|
|
|
Evolution of LVEF
大体时间:At 6,12, 24 and 36 months after randomization
|
Measurement of LVEF at inclusion and at each follow-up time point. The change in LVEF over time will be assessed relative to the date of inclusion and the preceding time point. |
At 6,12, 24 and 36 months after randomization
|
|
Evolution of Quality of life (EQ-5D)
大体时间:At 6, 12, 24 and 36 months after randomization
|
Measurement of EQ-5D at inclusion and at each follow-up time point. The change in EQ-5D over time will be assessed relative to the date of inclusion and the preceding time point. |
At 6, 12, 24 and 36 months after randomization
|
|
Incidence of Hospitalizations (all-cause, cardiovascular, HF-related)
大体时间:At 6, 12, 24 and 36 months after randomization
|
At 6, 12, 24 and 36 months after randomization
|
|
|
Incidence of Mortality (all-cause, cardiovascular, HF-related)
大体时间:At 6, 12, 24 and 36 months after randomization
|
Measurement of the cumulative incidence of all-cause, cardiovascular, and heart failure-related mortality at 6, 12, 24, and 36 months after randomization, based on the occurrence and documented cause of death. |
At 6, 12, 24 and 36 months after randomization
|
|
Medico-economic evaluation
大体时间:At 6, 12, 24 and 36 months after randomization
|
At 6, 12, 24 and 36 months after randomization
|
|
|
Complications related to pacemaker or ILR implantation
大体时间:At 6, 12, 24 and 36 months after randomization
|
At 6, 12, 24 and 36 months after randomization
|
|
|
Unscheduled pacemaker implantation in the ILR group
大体时间:At 6, 12, 24 and 36 months after randomization
|
At 6, 12, 24 and 36 months after randomization
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- RBHP 2025 ESCHALIER 2
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.